Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Malignant Melanoma (US)

Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: Excessive Use of Topical Anesthetics Can Be Fatal (www.medscape.com)
Compounded topical anesthetics can have dangerous side effects if used inappropriately over large surface areas, large amounts, under occlusion, for long periods, etc. Rational, supervised use is safe and very helpful in controlling pain in many outpatient laser and other procedures
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: No Need to Switch Retinoids During Acne Vulgaris Treatment (www.medscape.com)
This poster at the 2007 American Academy of Dermatology meeting in Washington, DC indicates that Galderma's product, Adapalene, is as effective as Allergan's product Tazarotene. This is opposite to 2 other studies that have been done in the past indicating that Tazarotene is the most effective retinoid,...
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: Obagi Medical Products, Inc. Launches CLENZIderm M.D. Penetrating Acne Therapeutic System (www.pharmalive.com)
Obagi Medical Products Clenziderm should have a positive impact:1. It allows the physician or the medical aesthetician under the physician’s guidance to dispense an effective product without a prescription.2. Its efficacy may approach that of prescription products, and studies are needed to confirm...
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: Ceragenix Completes Patient Visits for EpiCeram Clinical Study (www.pharmalive.com)
Ceragenix's new product Epiceram, the Barrier repair cream has potential merit and efficacy comparable to mid strength topical steroids:1. Barrier repair has been found to be antiinflammatory.2. The product in mouse studies has effects comparable to steroid creams.3. The product will have less/ minimal...
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: Centocor, Inc. Releases Phase 2 Data on Novel Biologic CNTO 1275 Targeting Chronic Plaque Psoriasis (pharmalive.com)
Centocor's product CNTO1275 will have a major and sustained impact on the market:1. Its PASI 75 reduction is better than the current injectables other than Centocor's Infliximab, which requires a complicated IV infusion.2. Side effects are comparable to other agents.3. It is specifically being developed...
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: Palomar and Gillette Expand Their Collaboration to Develop and Commercialize an Additional Light-Based Hair Removal Device for Home Use (phx.corporate-ir.net)
Implications: Palomar and Gillette’s venture in the direct to consumer sale of a light based laser device has several issues that will effect the ability of this venture to be successful 1. The device is only approved for non facial areas, and is only temporarily effective with less than 10% reduction-...
November 27, 2006
The favorite drug
Analysis of: FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy (www.ptcommunity.com)
1. Herceptin is one of the favorite drugs used by oncologists2. Optimal schedule and length is not clear3. Role of additional testing is not established4. Competition is around the corner
Analysis of: Cell Therapeutics: Xyotax faces more developmental delays (www.pharmaceutical-business-review.com)
Implications: 1. Drug will be delayed further2. Abraxane and Epothilone B will be approved. 3. If management understood that approach of early 80s does not work now, the drug would be available on market years ago.  
Analysis of: NICE rejects use of cancer drug Tarceva (www.pharmaceutical-business-review.com)
1. The first working drug will not be approved because it is too expensive.2. Narrow indication: never smoker, EGFR (+) would likely be approved if submitted, but that would establish the precedent and affect many other drugs3. US regulatory authorities may follow suite.

Previous Page : 6 7 8 9 10 11 12 13 14 15 16151 to 159 of 159

Analytics


Generated at 2009-01-07T19:00:58.307